Society for Immunotherapy of Cancer

The Society for Immunotherapy of Cancer (SITC), previously known as The International Society for Biological Therapy of Cancer (iSBTc) is a professional society of influential scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Currently, SITC has more than 2,400 members, representing 22 medical specialties from 42 countries around the world, who are engaged in the research and treatment of cancer.

Society for Immunotherapy of Cancer (SITC)
Formation1984
TypeNon-Profit Medical Society
HeadquartersMilwaukee, WI
Location
  • Milwaukee, Wis.
Official language
English
Executive Director
Tara Withington
President
Mario Sznol, MD Yale School of Medicine
Key people
Vice President Patrick Hwu, MD, University of Texas MD Anderson Cancer Center

Secretary/Treasurer Kim A. Margolin, MD, City of Hope

Immediate Past President Lisa H. Butterfield, PhD, Parker Institute for Cancer Immunotherapy
Websitewww.sitcancer.org

Through emphasis on high-caliber scientific meetings, dedication to education and outreach activities, focus on initiatives of major importance to the field, and commitment to collaborations with like-minded organizations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community in an effort to make cancer immunotherapy one of the four standards of care and the word “cure” a reality for cancer patients living with this disease.

The goals of SITC are directed towards the rapid dissemination of information in these areas to expedite the safe transfer of both basic and applied research to the clinical setting.

Core Values
  • Interaction/Integration: Facilitate the exchange of information and education among basic and translational researchers, clinicians, young investigators, societies and groups sharing the mission of SITC
  • Innovation: Challenge the thinking and seek the best research in the development of cancer immunotherapy
  • Translation: Facilitate the transfer of cancer immunology and immunotherapy research from the bench to the clinic and back
  • Leadership: Define what is new and important and effectively communicate it to all relevant stakeholders

[1]

Goals
  • Collaboration: Cultivate meaningful relationships with key strategic partners.
  • Engagement: Create a network of cancer immunotherapy stakeholders, providing greater opportunities for engagement and interaction.
  • Education and Scientific Exchange: Serve as the leading resource for information and education on cancer immunotherapy.
  • Global Impact: Advance the science and application of cancer immunotherapy world-wide.
  • Science and Research: Challenge the thinking and seek the best research in the exploration and development of tumor immunology and cancer immunotherapy.

Annual Meeting & Pre-Conference Programs

The Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy.

As the largest conference solely focused on cancer immunotherapy, the Annual Meeting & Pre-Conference Programs provides more than 5,000 international leaders from academia, regulatory and government agencies, as well as industry representatives with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients.[2]

Activities

SITC continues to increase the number of programs it offers [3] each year. The purpose of these programs – which include the Annual Meeting & Pre-Conference Programs, Advances in Cancer Immunotherapy™ educational series, and an array of collaborative education programs – is to bring together leaders to discuss the latest developments in cancer immunotherapy and biological therapy, and to focus on and educate the clinical and translational aspects of biologic approaches to cancer treatment.[4]

Membership

SITC's membership consists of leaders in the field of cancer immunotherapy and up-and-coming scientists. This group includes research scientists, physician scientists, clinicians, patients, patient advocates, government representatives and industry leaders. In 2018, SITC grew to more than 2,400 members, representing 22 medical specialties and 42 countries around the world and are engaged in research and treatment of cancer.[5]

Publications

The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). It is an open access, online journal created by the Society for the many stakeholders in the tumor immunology and cancer immunotherapy community. JITC is an outlet and targeted publication platform dedicated to advancing the science of tumor immunology and cancer immunotherapy.[6]

gollark: It's highly advanced.
gollark: This is "minoteaur" version 5ish.
gollark: Just log in with the password "this can be anything whatsoever it doesn't check".
gollark: https://minoteaur.osmarks.net/bees <@!747067747569106974>
gollark: ·

References
  1. "Core Values". About SITC. Retrieved 24 August 2016.
  2. (SITC), Society for Immunotherapy of Cancer. "SITC Annual Meeting & Pre-Conference Programs - Society for Immunotherapy of Cancer (SITC)". www.sitcancer.org. Retrieved 2017-10-13.
  3. "Upcoming Events - Society for Immunotherapy of Cancer (SITC)". Sitcancer.org. Retrieved 2020-04-06.
  4. "Meetings". SITC Meetings. Retrieved 18 March 2013.
  5. "General Society". General Society. Retrieved 18 March 2013.
  6. "JITC". About the Journal. Retrieved 18 March 2013.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.